Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

5 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • Meropenem Fresenius KabiRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION/INFUSION

    View study and source
  • Meropenem Fresenius KabiRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION/INFUSION

    View study and source
  • MEROPENEM TRIHYDRATERegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: POWDER FOR SOLUTION FOR INJECTION/INFUSION

    View study and source
  • Meropenem AptaPharma 1 g injektio-/infuusiokuiva-aine, liuosta vartenRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION/INFUSION

    View study and source
  • Meropenem Fresenius Kabi 1 g pulver till injektionsvätska eller infusionsvätska, lösningRegistry product

    Linked study entry; product equivalence not established

    Formulation reported by source: SOLUTION FOR INJECTION/INFUSION

    View study and source

Success Metrics

Active Trials
1(25%)

Phase Distribution

Phase 3
1
25%
Phase 4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Other(1)

Detailed Status

Not yet recruiting2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
N/A

Trials by Phase

Phase 31 (50.0%)
Phase 41 (50.0%)

Trials by Status

not_yet_recruiting250%
recruiting125%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
unknownphase_4

Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia

NCT03514446
not_yet_recruiting

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

SYF623f1fb0b18e456ebff0e106757d3dc0
not_yet_recruitingphase_3

LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial

SYF6b9988cb18b94ba6883d7b84e729b9b1
recruiting

Accelerated treatment of infectious endocarditis

SYFa625aefdf2e54c5fbcbbb8490c81b89f

Clinical Trials (4)

Showing 4 of 4 trials
NCT03514446Phase 4

Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia

Unknown
SYF623f1fb0b18e456ebff0e106757d3dc0

BETARGET : Randomized trial of individualizing BETA-lactam taRGET combining therapeutic drug monitoring, minimal inhibitory concentration and model-based dose adjustment, in Intensive Care Units patients with gram negative bacilli infection

Not Yet Recruiting
SYF6b9988cb18b94ba6883d7b84e729b9b1Phase 3

LIBRETTO: Stimulan™ Local Antibiotic Delivery System Versus 4-Week Systemic Antibiotic Therapy for Diabetic Foot Osteomyelitis – A Prospective, Randomized, Controlled Trial

Not Yet Recruiting
SYFa625aefdf2e54c5fbcbbb8490c81b89f

Accelerated treatment of infectious endocarditis

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
Type not reported
Total Trials
4